# Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II

Study · id `cardio:ct-nct07134712` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07134712](<https://clinicaltrials.gov/study/NCT07134712>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07134712

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 102 participants.

## Technical summary

Registry record NCT07134712. Randomized; single masking; primary purpose treatment. Start 2026-03-30 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (planned count; ClinicalTrials.gov record NCT07134712, source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)
- Planned start: 2026-03-30 (anticipated) (ClinicalTrials.gov record NCT07134712, source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07134712, source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07134712, source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)
- Countries: Australia; Taiwan (ClinicalTrials.gov record NCT07134712, source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07134712-2026-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II
- Acronym: SEMIAMI
- Condition: Acute Myocardial Infarction (AMI)
- Intervention (Biological): Cord Blood Nucleated cells
- Lead sponsor: HONYA Medical Co Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: 8f4b7ee3b8576478a19a20e59358fe3705be5b4c697c3ad5422eba92fdca2fa7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
